
Could anti-PD-L1 be the best choice as front-line therapy in platinum-ineligible patients with NSCLC?

The first randomised study of peptide receptor radionuclide therapy in pancreatic NETs met its primary endpoint

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.